These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21332415)

  • 1. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
    Szabó N; Kincses ZT; Vécsei L
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):441-55. PubMed ID: 21332415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
    Kalda A; Yu L; Oztas E; Chen JF
    J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on adenosine A2A receptors as drug target in Parkinson's disease.
    Vallano A; Fernandez-Duenas V; Pedros C; Arnau JM; Ciruela F
    CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):659-69. PubMed ID: 21838670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
    Jenner P
    Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Istradefylline for the treatment of Parkinson's disease.
    Park A; Stacy M
    Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
    Kulisevsky J; Poyurovsky M
    Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do caffeine and more selective adenosine A
    Chen JF; Schwarzschild MA
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A2A receptors in neuroprotection of dopaminergic neurons.
    Pedata F; Pugliese AM; Melani A; Gianfriddo M
    Neurology; 2003 Dec; 61(11 Suppl 6):S49-50. PubMed ID: 14663010
    [No Abstract]   [Full Text] [Related]  

  • 10. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
    Chen JF
    Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
    Xu K; Bastia E; Schwarzschild M
    Pharmacol Ther; 2005 Mar; 105(3):267-310. PubMed ID: 15737407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occupancy of adenosine A
    Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
    Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
    Jenner P
    Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
    Mori A
    Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
    Ceiślak M; Komoszyński M
    Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of istradefylline for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the adenosine A
    Zhao Y; Zhou YG; Chen JF
    Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.
    Pinna A
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1619-31. PubMed ID: 19888872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
    Matsubara E; Shoji M; Abe K
    Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2A receptor antagonists as novel anti-Parkinsonian agents: a review of structure-activity relationships.
    Azam F; Ibn-Rajab IA; Alruiad AA
    Pharmazie; 2009 Dec; 64(12):771-95. PubMed ID: 20095134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.